Modification of dendritic cells with interferon-γ -inducible protein-10 gene to enhance vaccine potency

Tae Heung Kang, Hyun Cheol Bae, Seok Ho Kim, Soo-Hong Seo, Sang Wook Son, Eun Young Choi, Seung Yong Seong, Tae Woo Kim

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Dendritic cell (DC)-based vaccines have become a promising modality in cancer immunotherapy. However, their ability to initiate tumor antigen-specific T cell immunity is limited in various negative-feedback mechanisms. The rapid down-regulation of chemokines, such as the interferon inducible protein of 10 kDa (IP-10), which chemoattracts activated antigen-specific CD8+ T cells, would represent negative-feedback regulation. Therefore, we attempted to improve DC vaccine potency by introducing the IP-10 gene retrovirally aiming to replenish the chemoattractive activity of DCs. Methods: We introduced IP-10 gene into DC2.4 cells, referred to as DC-IP10, using a retroviral system. Nonsecretable mIP-10-expressing DCs (DC-mIP10) were also prepared to evaluate the effects of secretion in IP-10-mediated modulation of DC biology. Additionally, in vitro and in vivo activation of antigen-specific T lymphocytes and in vivo anti-tumor effects induced by DC-IP10 or DC-mIP10 were determined. Results: The modification of DC2.4 cells with the IP-10 gene resulted in the secretion of functionally chemoattractive IP-10 and, unexpectedly, a significant up-regulation of surface expression in co-stimulatory molecules, such as CD40 and CD80, compared to that of DCs with vector control (DC-no insert). DC-mIP10 also displayed the partially matured phenotypes but failed to recruit antigen-specific T cells in an in vitro cell culture system. Consistently, DC-IP10 generated more tumor antigen-specific CD8+ T cells and stronger anti-tumor effects in vaccinated mice than did control DCs and DC-mIP10. Conclusions: The results obtained provide the groundwork for a future clinical translation of the chemokine-based genetic modification of DCs to increase their vaccine potency.

Original languageEnglish
Pages (from-to)889-898
Number of pages10
JournalJournal of Gene Medicine
Volume11
Issue number10
DOIs
Publication statusPublished - 2009 Dec 28

Fingerprint

Vaccine Potency
Chemokine CXCL10
Dendritic Cells
Genes
T-Lymphocytes
Neoplasm Antigens
Chemokines
CD8 Antigens
Antigens
Neoplasms
Immunotherapy
Cell Biology
Immunity

Keywords

  • Cancer vaccine
  • Chemokine
  • Dendritic cell
  • Immunotherapy
  • IP-10

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery

Cite this

Modification of dendritic cells with interferon-γ -inducible protein-10 gene to enhance vaccine potency. / Kang, Tae Heung; Bae, Hyun Cheol; Kim, Seok Ho; Seo, Soo-Hong; Son, Sang Wook; Choi, Eun Young; Seong, Seung Yong; Kim, Tae Woo.

In: Journal of Gene Medicine, Vol. 11, No. 10, 28.12.2009, p. 889-898.

Research output: Contribution to journalArticle

Kang, Tae Heung ; Bae, Hyun Cheol ; Kim, Seok Ho ; Seo, Soo-Hong ; Son, Sang Wook ; Choi, Eun Young ; Seong, Seung Yong ; Kim, Tae Woo. / Modification of dendritic cells with interferon-γ -inducible protein-10 gene to enhance vaccine potency. In: Journal of Gene Medicine. 2009 ; Vol. 11, No. 10. pp. 889-898.
@article{cbbc9656ac1a421492e9815968b9df09,
title = "Modification of dendritic cells with interferon-γ -inducible protein-10 gene to enhance vaccine potency",
abstract = "Background: Dendritic cell (DC)-based vaccines have become a promising modality in cancer immunotherapy. However, their ability to initiate tumor antigen-specific T cell immunity is limited in various negative-feedback mechanisms. The rapid down-regulation of chemokines, such as the interferon inducible protein of 10 kDa (IP-10), which chemoattracts activated antigen-specific CD8+ T cells, would represent negative-feedback regulation. Therefore, we attempted to improve DC vaccine potency by introducing the IP-10 gene retrovirally aiming to replenish the chemoattractive activity of DCs. Methods: We introduced IP-10 gene into DC2.4 cells, referred to as DC-IP10, using a retroviral system. Nonsecretable mIP-10-expressing DCs (DC-mIP10) were also prepared to evaluate the effects of secretion in IP-10-mediated modulation of DC biology. Additionally, in vitro and in vivo activation of antigen-specific T lymphocytes and in vivo anti-tumor effects induced by DC-IP10 or DC-mIP10 were determined. Results: The modification of DC2.4 cells with the IP-10 gene resulted in the secretion of functionally chemoattractive IP-10 and, unexpectedly, a significant up-regulation of surface expression in co-stimulatory molecules, such as CD40 and CD80, compared to that of DCs with vector control (DC-no insert). DC-mIP10 also displayed the partially matured phenotypes but failed to recruit antigen-specific T cells in an in vitro cell culture system. Consistently, DC-IP10 generated more tumor antigen-specific CD8+ T cells and stronger anti-tumor effects in vaccinated mice than did control DCs and DC-mIP10. Conclusions: The results obtained provide the groundwork for a future clinical translation of the chemokine-based genetic modification of DCs to increase their vaccine potency.",
keywords = "Cancer vaccine, Chemokine, Dendritic cell, Immunotherapy, IP-10",
author = "Kang, {Tae Heung} and Bae, {Hyun Cheol} and Kim, {Seok Ho} and Soo-Hong Seo and Son, {Sang Wook} and Choi, {Eun Young} and Seong, {Seung Yong} and Kim, {Tae Woo}",
year = "2009",
month = "12",
day = "28",
doi = "10.1002/jgm.1371",
language = "English",
volume = "11",
pages = "889--898",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Modification of dendritic cells with interferon-γ -inducible protein-10 gene to enhance vaccine potency

AU - Kang, Tae Heung

AU - Bae, Hyun Cheol

AU - Kim, Seok Ho

AU - Seo, Soo-Hong

AU - Son, Sang Wook

AU - Choi, Eun Young

AU - Seong, Seung Yong

AU - Kim, Tae Woo

PY - 2009/12/28

Y1 - 2009/12/28

N2 - Background: Dendritic cell (DC)-based vaccines have become a promising modality in cancer immunotherapy. However, their ability to initiate tumor antigen-specific T cell immunity is limited in various negative-feedback mechanisms. The rapid down-regulation of chemokines, such as the interferon inducible protein of 10 kDa (IP-10), which chemoattracts activated antigen-specific CD8+ T cells, would represent negative-feedback regulation. Therefore, we attempted to improve DC vaccine potency by introducing the IP-10 gene retrovirally aiming to replenish the chemoattractive activity of DCs. Methods: We introduced IP-10 gene into DC2.4 cells, referred to as DC-IP10, using a retroviral system. Nonsecretable mIP-10-expressing DCs (DC-mIP10) were also prepared to evaluate the effects of secretion in IP-10-mediated modulation of DC biology. Additionally, in vitro and in vivo activation of antigen-specific T lymphocytes and in vivo anti-tumor effects induced by DC-IP10 or DC-mIP10 were determined. Results: The modification of DC2.4 cells with the IP-10 gene resulted in the secretion of functionally chemoattractive IP-10 and, unexpectedly, a significant up-regulation of surface expression in co-stimulatory molecules, such as CD40 and CD80, compared to that of DCs with vector control (DC-no insert). DC-mIP10 also displayed the partially matured phenotypes but failed to recruit antigen-specific T cells in an in vitro cell culture system. Consistently, DC-IP10 generated more tumor antigen-specific CD8+ T cells and stronger anti-tumor effects in vaccinated mice than did control DCs and DC-mIP10. Conclusions: The results obtained provide the groundwork for a future clinical translation of the chemokine-based genetic modification of DCs to increase their vaccine potency.

AB - Background: Dendritic cell (DC)-based vaccines have become a promising modality in cancer immunotherapy. However, their ability to initiate tumor antigen-specific T cell immunity is limited in various negative-feedback mechanisms. The rapid down-regulation of chemokines, such as the interferon inducible protein of 10 kDa (IP-10), which chemoattracts activated antigen-specific CD8+ T cells, would represent negative-feedback regulation. Therefore, we attempted to improve DC vaccine potency by introducing the IP-10 gene retrovirally aiming to replenish the chemoattractive activity of DCs. Methods: We introduced IP-10 gene into DC2.4 cells, referred to as DC-IP10, using a retroviral system. Nonsecretable mIP-10-expressing DCs (DC-mIP10) were also prepared to evaluate the effects of secretion in IP-10-mediated modulation of DC biology. Additionally, in vitro and in vivo activation of antigen-specific T lymphocytes and in vivo anti-tumor effects induced by DC-IP10 or DC-mIP10 were determined. Results: The modification of DC2.4 cells with the IP-10 gene resulted in the secretion of functionally chemoattractive IP-10 and, unexpectedly, a significant up-regulation of surface expression in co-stimulatory molecules, such as CD40 and CD80, compared to that of DCs with vector control (DC-no insert). DC-mIP10 also displayed the partially matured phenotypes but failed to recruit antigen-specific T cells in an in vitro cell culture system. Consistently, DC-IP10 generated more tumor antigen-specific CD8+ T cells and stronger anti-tumor effects in vaccinated mice than did control DCs and DC-mIP10. Conclusions: The results obtained provide the groundwork for a future clinical translation of the chemokine-based genetic modification of DCs to increase their vaccine potency.

KW - Cancer vaccine

KW - Chemokine

KW - Dendritic cell

KW - Immunotherapy

KW - IP-10

UR - http://www.scopus.com/inward/record.url?scp=72449175976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449175976&partnerID=8YFLogxK

U2 - 10.1002/jgm.1371

DO - 10.1002/jgm.1371

M3 - Article

C2 - 19618483

AN - SCOPUS:72449175976

VL - 11

SP - 889

EP - 898

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 10

ER -